Profile data is unavailable for this security.
About the company
Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.
- Revenue in USD (TTM)9.96m
- Net income in USD-169.06m
- Incorporated2016
- Employees174.00
- LocationGeneration Bio Co301 BINNEY STREETCAMBRIDGE 02142United StatesUSA
- Phone+1 (857) 529-5908
- Fax+1 (302) 655-5049
- Websitehttps://generationbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lineage Cell Therapeutics Inc | 8.00m | -23.66m | 192.60m | 75.00 | -- | 2.66 | -- | 24.07 | -0.1344 | -0.1344 | 0.0455 | 0.3836 | 0.0722 | -- | 57.16 | 106,706.70 | -21.32 | -19.53 | -24.82 | -22.59 | 91.88 | 89.13 | -295.30 | -370.88 | -- | -- | 0.0018 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
| Caribou Biosciences Inc | 33.40m | -115.26m | 193.73m | 158.00 | -- | 0.5643 | -- | 5.80 | -1.45 | -1.45 | 0.4136 | 3.80 | 0.0886 | -- | 11.68 | 211,417.70 | -30.56 | -- | -33.02 | -- | -- | -- | -345.05 | -- | -- | -- | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Scilex Holding Co | 47.05m | -160.60m | 197.50m | 106.00 | -- | -- | -- | 4.20 | -1.28 | -1.28 | 0.3905 | -1.79 | 0.5307 | 5.53 | 1.92 | 448,047.60 | -121.78 | -- | -- | -- | 66.14 | -- | -229.47 | -- | 0.1356 | -12.49 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
| Coherus Biosciences Inc | 301.87m | -59.29m | 201.92m | 249.00 | -- | -- | -- | 0.6689 | -0.7801 | -0.7801 | 2.86 | -0.7211 | 0.5178 | 3.17 | 1.71 | 986,506.60 | -10.17 | -21.43 | -23.51 | -29.32 | 41.46 | 79.01 | -19.64 | -36.56 | 1.05 | -3.87 | 1.21 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Boundless Bio Inc | -100.00bn | -100.00bn | 202.07m | 72.00 | -- | -- | -- | -- | -- | -- | -- | 4.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| Prelude Therapeutics Inc | 0.00 | -125.55m | 202.69m | 128.00 | -- | 0.9617 | -- | -- | -1.88 | -1.88 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -56.37 | -47.21 | -61.52 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| TriSalus Life Sciences Inc | 21.98m | -68.07m | 203.42m | 112.00 | -- | -- | -- | 9.25 | -2.09 | -2.09 | 0.7291 | -1.31 | 1.17 | 1.26 | 7.49 | 196,276.80 | -339.18 | -- | -11,196.50 | -- | 86.74 | -- | -291.08 | -- | 0.714 | -16.82 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Generation Bio Co | 9.96m | -169.06m | 203.58m | 174.00 | -- | 1.54 | -- | 20.43 | -2.56 | -2.56 | 0.1509 | 1.99 | 0.0278 | -- | 10.98 | 57,258.62 | -47.14 | -36.96 | -50.75 | -39.21 | -- | -- | -1,696.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Zevra Therapeutics Inc | 28.01m | -50.90m | 204.25m | 65.00 | -- | 4.18 | -- | 7.29 | -1.34 | -1.34 | 0.7513 | 1.17 | 0.2172 | -- | 3.47 | 430,876.90 | -39.48 | -32.11 | -47.94 | -39.89 | 51.11 | -- | -181.75 | -128.42 | -- | -- | 0.4929 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Elevation Oncology Inc | 0.00 | -39.35m | 206.53m | 29.00 | -- | 2.58 | -- | -- | -1.03 | -1.03 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -42.35 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -12.50 | 0.2889 | -- | -- | -- | 51.93 | -- | -- | -- |
| Renovaro Inc | 0.00 | -53.93m | 207.98m | 11.00 | -- | 1.23 | -- | -- | -0.7661 | -0.7661 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -37.06 | -27.81 | -41.75 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| XBiotech Inc | 0.00 | -30.74m | 211.38m | 92.00 | -- | 1.01 | -- | -- | -1.01 | -1.01 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | -13.08 | 31.88 | -13.68 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0456 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Ovid Therapeutics Inc | 473.53k | -50.68m | 214.25m | 40.00 | -- | 2.73 | -- | 452.46 | -0.7174 | -0.7174 | 0.0067 | 1.11 | 0.0034 | -- | -- | 11,838.25 | -36.86 | -20.78 | -39.08 | -23.27 | -- | -- | -10,701.91 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| 2Seventy Bio Inc | 71.20m | -223.22m | 214.87m | 274.00 | -- | 1.04 | -- | 3.02 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Invivyd Inc | 0.00 | -206.82m | 215.96m | 94.00 | -- | 1.21 | -- | -- | -1.86 | -1.86 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -73.08 | -- | -81.48 | -- | -- | -- | -- | -- | 5.77 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
Data as of Jun 07 2024. Currency figures normalised to Generation Bio Co's reporting currency: US Dollar USD
49.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 8.78m | 13.21% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 5.33m | 8.02% |
| Bellevue Asset Management AGas of 31 Mar 2024 | 3.86m | 5.81% |
| Invus Public Equities Advisors LLCas of 31 Mar 2024 | 2.83m | 4.26% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.79m | 4.20% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.53m | 3.80% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 2.12m | 3.19% |
| EcoR1 Capital, LLCas of 31 Mar 2024 | 2.05m | 3.08% |
| PFM Health Sciences LPas of 31 Mar 2024 | 1.62m | 2.44% |
| DWS Investments (UK) Ltd.as of 31 Mar 2024 | 1.25m | 1.88% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
